Artículo de Revisión
Referencias
1.- Bewtra M, Kaiser LM, TenHave T, Lewis
JD. Crohn´s Disease and ulcerative colitis
are associated with elevated standardized
mortality ratios: A meta-analysis.
Inflamm Bowel Dis 2013; 19: 599-613.
2.- Bitton A, Vutcovici M, Sewitch M,
Suissa S, Brassard P. Mortality trends in
Crohn´s disease and ulcerative colitis:
A population-based study in Quebec,
Canada. Inflamm Bowel Dis 2016; 22:
416-23.
3.- Chu TPC, Moran GW, Card TR. The
pattern of underlying cause of death in
patients with inflammatory bowel disease
in England: A record linkage study. J
Crohns Colitis 2017; 11: 578-85.
4.- Cosnes J. Smoking, physical activity,
nutrition and lifestyle: Environmental
factors and their impact on IBD. Dig Dis
2010; 2: 411-7.
5.- Magro F, Gionchetti P, Eliakim R,
Ardizzone S, Armuzzi A, Barreirode
Acosta M, et al. Third European
Evidence-based Consensus on Diagnosis
and Management of Ulcerative
Colitis Part 1: Definitions, diagnosis,
extraintestinal manifestations, pregnancy,
cancer surveillance, surgery, and ileo-anal
pouch disorders. J Crohns Colitis 2017;
11: 649-70.
6.- Sands BE. Fulminant Colitis. J
Gastrointestinal Surg 2008; 12: 2157-9.
7.- Sobrado CW, Sobrado LF. Management
of acute severe ulcerative colitis: A
clinical Update. Arq Bras Cir Dig 2016;
29: 201-5.
8.- Hernández-Rocha C, Ibáñez P, Molina
ME, Klaassen J, Valenzuela A, Candia
R, et al. Diagnóstico y manejo de colitis
ulcerosa grave. Una mirada actualizada.
Rev Med Chile 2017; 145: 96-105.
9.- Ferrer M, Hernández A, Reina A, Rosado
R. Current status of the treatment of
fulminant colitis. Cir Esp 2015; 93: 276-
82.
10.- Van Assche G, Vermeire S, Rutgeerts P.
Management of acute severe ulcerative
colitis. Gut 2011; 60: 130-3.
11.- McLean LP, Cross RK. Adverse events
in IBD: to stop or continue immune
suppressant and biologic treatment.
Expert Rev Gastroenterol Hepatol 2014;
8: 223-40.
12.- Barreiro M, Seijo S, Domínguez JE. Lifethreatening
236
Mort ali dad en enferme dad infl amatori a intestin al - A. Jiménez H. et al.
acute lower gastrointestinal
bleeding in patients with Crohn´s disease.
Rev Esp Enferm Dig 2007; 99: 388-91.
13.- Martin V, Rubí AR, Chaparro M,
Jusué V, Friera A, Gisbert JP. Arterial
embolization in the treatment of massive
lower gastrointestinal bleeding in patients
with Crohn´s disease. Gastroenterol
Hepatol 2013; 36: 574-6.
14.- Ortiz V, Nicolás D, Nos P, Berenguer J.
Severe lower digestive hemorrhage in
Crohn’s Disease. Gastroenterol Hepatol
1999; 22: 18-21.
15.- Kim KJ, Han BJ, Yang SK, Na SY,
Park SK, Boo SJ, et al. Risk factors
and outcome of acute severe lower
gastrointestinal bleeding in Crohn’s
Disease. Dig Liver Dis 2012; 44; 723-8.
16.- Podugu A, Tandon K, Castro FJ.
Crohn´s Disease presenting as acute
gastrointestinal hemorrhage. World J
Gastroenterol 2016; 22: 4073-8.
17.- Mallant-Hent RCh, van Bodegraven AA,
Meuwissen SG, Manoliu RA. Alternative
approach to massive gastrointestinal
bleeding in ulcerative colitis: highly
selective transcatheter embolization. Eur
J Gastroenterol Hepatol 2003; 15: 189-
93.
18.- Kassam Z, Belga S, Roifman I, Hirota S,
Jijon H, Kaplan GG, et al. Inflammatory
bowel disease cause-specific mortality: a
primer for clinicians. Inflamm Bowel Dis
2014; 20: 2483-92.
19.- Suárez Ferrer C, Vera Mendoza MI, Amo
San Román L, González Lama Y, Calvo
Moya M, García Casas M, et al. Risk
of thromembolic phenomena in patients
with inflammatory bowel disease.
Gastroenterol Hepatol 2012; 35: 634-9.
20.- Beaugerie L, Itzkowitz SH. Cancer
complicating inflammatory bowel
disease. N Engl J Med 2015; 372: 1441-
52.
21.- Velayos F. Managing risks of neoplasia
in inflammatory bowel disease. Curr
Gastroenterol Rep 2012; 14: 174-80.
22.- Chang M, Chang L, Chang HM, Chang
F. Intestinal and extra-intestinal cancers
associated with inflammatory bowel
disease. Clin Colorectal Cancer 2017; Jun
27 (Publicación electrónica en avance).
23.- Bojesen RD, Riis LB, Hogdall E, Nielsen
OH, Jess T. Inflammatory bowel disease
and small bowel cancer risk, clinical
characteristics and histopathology:
A population-based study. Clin
Gastroenterol Hepatol 2017: Jul 8
(Publicación electrónica en avance).
24.- Canavan C, Abrams KR, Mayberry J.
Meta-analysis: colorectal and small
bowel cancer risk in patients with
Crohn’s disease. Aliment Pharmacol
Ther. 2006; 23: 1097-104.
25.- Palascak-Juif V, Bouvier AM, Cosnes
J, Flourié B, Bouché O, Cadiot G, et al.
Small bowel adenocarcinoma in patients
with Crohn’s Disease compared with
small bowel adenocarcinoma de novo.
Inflamm Bowel Dis 2005; 11: 828-32.
26.- Burisch J, Jess T, Martinato M, Lakatos
PL; ECCO-EpiCom. The burden of
inflammatory bowel disease in Europe. J
Crohns Colitis 2013; 7: 322-37.
27.- Quera R, Simian D, Flores L. Neoplasias
extracolónicas en pacientes con
enfermedad inflamatoria intestinal.
Gastroenterol latinoam 2017; 28: 25-30.
28.- Gesualdo M, Scicchitano P, Carbonara
S, Ricci G, Principi M, Lerardi E, et al.
The association between cardiac and
gastrointestinal disorders: causal o casual
link? J Cardiovasc Med 2016; 17: 330-8.
29.- Fumery M, Xiacocang C, Dauchet L,
Gower-Rousseau C, Peyrin-Biroulet L,
Colomel JF. Thromboembolic events and
cardiovascular mortality in inflammatory
bowel diseases: a meta-anaylisis of
observational studies. J Crohns Colitis
2014; 8: 469-79.
30.- Taous A, Berri MA, Lamsiah T, Zainoun
B, Ziadi T, Rouimi A. Cerebral venous
thrombosis revealing an ulcerative colitis.
Pan Afr Med J 2016; 23: 120.
31.- Rahier JF, Ben-Horin S, Chowers Y,
Conlon C, De Munter P, D’Haens G, et
al. European evidence-based consensus
on the prevention, diagnosis and
management of opportunistic infections
in inflammatory bowel disease. J Crohns
Colitis 2009; 3: 47-91.
32.- Zabana Y, Domenech E, Mañosa M,
García-Planella E, Bernal I, Cabré E, et
al. Infliximab safety profile and longterm
applicability in inflammatory bowel
disease: 9-year experience in clinical
practice. Aliment Pharmacol Ther 2010;
31: 553-60.
Gastroenterol. latinoam 2017; Vol 28, Nº 4: 231-237